[Updates on antiphospholipid syndrome].

Authors

Yuichiro Fujieda

Published in

[Rinsho ketsueki] The Japanese journal of clinical hematology. Volume 67. Issue 6. Pages 592-599.

Abstract

Antiphospholipid syndrome (APS) is characterized by recurrent arteriovenous thrombosis and pregnancy complications associated with persistent antiphospholipid antibodies (aPL). The 2023 ACR/EULAR classification criteria introduced a scoring system incorporating microvascular disease, cardiac valve disease, and thrombocytopenia. However, these criteria are designed for research classification rather than clinical diagnosis. In laboratory testing, the expanding use of automated immunoassays necessitates inter-assay standardization. Risk stratification integrates quantitative aPL assessment, including triple positivity, aPL score, and Global APS Score (GAPSS), with conventional cardiovascular risk factors. For thrombotic APS, direct oral anticoagulants should be avoided in high-risk patients. Disease activity assessment has advanced with the development of EAPSDAS and the monocyte-to-HDL cholesterol ratio. These advances are expected to facilitate a paradigm shift toward precision medicine in APS management.

PMID:
42419993
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.